Chordia Therapeutics is focused on developing targeted therapies in oncology to improve treatment outcomes for cancer patients. The company aims to address the limitations of current cancer treatments by utilizing precision medicine approaches to tailor therapies based on individual tumor profiles.
Funding
$26.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JKUFounders
Product
Problem
Current cancer treatments often face limitations due to their broad approach, leading to off-target effects and varying efficacy across patients. This necessitates more precise and personalized therapies that can target specific tumor characteristics.
Solution
Chordia Therapeutics develops targeted oncology therapies designed to improve outcomes for cancer patients by addressing the limitations of existing treatments. The company utilizes precision medicine to tailor therapies based on individual tumor profiles, focusing on specific molecular targets and pathways critical for cancer growth and survival. By identifying and targeting these unique vulnerabilities, Chordia aims to develop more effective and less toxic treatments. Their approach involves advanced molecular profiling and drug discovery techniques to identify promising therapeutic candidates. These candidates are then rigorously evaluated in preclinical and clinical studies to assess their safety and efficacy.
Target Audience
Chordia Therapeutics' primary target audience includes cancer patients with specific genetic or molecular profiles, as well as oncologists and other healthcare professionals involved in their care.
Features
- Focus on small molecule drug development targeting specific cancer-driving proteins.
- Utilizes advanced genomic and proteomic profiling to identify patient populations most likely to respond to their therapies.
- Employs rational drug design and medicinal chemistry to optimize drug candidates for potency, selectivity, and bioavailability.
- Conducts preclinical studies using patient-derived xenografts and other relevant models to predict clinical efficacy.
- Develops companion diagnostics to identify patients who will benefit most from their targeted therapies.